DARE to PLAY Sildenafil Cream

Search documents
Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream
Globenewswire· 2025-07-29 12:00
Core Insights - Daré Bioscience, Inc. has announced the launch of DARE to PLAY Sildenafil Cream, a topical formulation aimed at improving women's sexual arousal, set to be available by prescription in Q4 2025 [1][9] - The product is clinically proven to enhance genital blood flow and sexual response, differentiating it from untested compounded products [2] - A consumer awareness campaign has been initiated in collaboration with Rosy Wellness to educate women about sexual health and the benefits of DARE to PLAY [3][8] Product Details - DARE to PLAY Sildenafil Cream contains sildenafil, the same active ingredient found in Viagra, specifically formulated for women [2] - The product aims to address the long-standing gap in women's sexual health solutions, providing a clinically backed option for those experiencing arousal concerns [2][11] Campaign and Educational Initiatives - The campaign includes the release of educational content and interactive modules designed to inform women about physical arousal and how DARE to PLAY can assist them [3][6] - Quickies, short-form videos reviewed for clinical accuracy, will combat misinformation and provide trustworthy education on female sexual health [4][5] - The Arousal Collection offers a deeper exploration of physical arousal, authored by Dr. Sameena Rahman, to guide women through understanding their sexual health [6][7] Collaboration and Community Engagement - The partnership with Rosy Wellness aims to empower women through evidence-based resources and community support, enhancing access to sexual health information [8][10] - The campaign represents a commitment to advancing sexual health equity and ensuring women have the necessary information and solutions [8] Company Background - Daré Bioscience focuses on addressing unmet needs in women's health, with a portfolio that includes innovative solutions for contraception, sexual health, and menopause [11][12] - The company aims to bring products to market that leverage existing clinical proof of concept, optimizing access for women in a fiscally responsible manner [11]
Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream
Globenewswire· 2025-06-04 12:00
Core Insights - Daré Bioscience, Inc. has announced a strategic collaboration with Rosy Wellness to support the marketing and awareness campaign for its DARE to PLAY Sildenafil Cream, aimed at enhancing women's sexual health [1][3][4] Company Overview - Daré Bioscience is a biopharmaceutical company focused on women's health, aiming to address unmet needs through innovative solutions [10] - The company is set to start recording revenue in the fourth quarter of 2025 with the launch of DARE to PLAY Sildenafil Cream, a topical formulation of sildenafil citrate [1][2] Product Details - DARE to PLAY Sildenafil Cream is designed to increase local blood flow to genital tissues, addressing female sexual arousal disorder [2][11] - The product is expected to be available by prescription in the U.S. as a compounded drug under Section 503B of the FDCA [2] Collaboration Highlights - The partnership combines Daré's clinical expertise with Rosy's extensive digital reach and community engagement, which includes over 250,000 women [1][3] - The collaboration will focus on educational outreach and destigmatizing conversations around female sexual health [3][5] Market Context - Female sexual health is identified as a significantly underserved area, with 65% of women reporting concerns with arousal [3][4] - The partnership aims to enhance sexual wellness education and access for women, addressing a historically stigmatized topic [5][8]